期刊文献+

半自动化制备多种氟标药物模块的初步探讨 被引量:2

A Pilot Study of Semiautomatic Synthesis Module for Preparing Multiple Fluorine-18-labeled Radiopharmaceuticals
下载PDF
导出
摘要 改进现有设备实现18F-FLT和18F-FECh等多种氟标药物的半自动化制备。通过对美国CTI公司生产的18F-FDG化学合成模块(CPCU)改进并增加部分装置完成了以上药物的半自动化合成。经过多次实验,改造后的模块合成18F-FLT和18F-FECh的产率分别达到37.3%±3.1%和37.2%±4.7%,较手工操作分别提高了3倍和1倍,合成时间各由100 min和90 min缩短到50 min和45 min,产品的放化纯度均大于98%。该设备可半自动化合成多种氟标药物,为临床和科研工作带来了便利。 To improve FDG synthesis module Chemical Processing Control Unit (CPCU) manufactured by CTI for producing ^18F-FLT and ^18F-FECh, the ^18F-FDG module is modified. Additional devices are designed and added for performing the purification of fluorine- 18-labeled radiopharmaceuticals. Repeated experiments show that the radiochemical yields of 18F-FLT and 18F-FECh are (37.3±3.1)% and (37.2±4.7) %, and three times and one time higher than manual operation as well, the total synthesis time is shorten to 50 minutes and 45 minutes respectively. Radiochemical purities of both ^18F-FLT and ^18F-FECh are more than 98%. Multiple fluorine-18-1abeled radiopharmaceuticals can be prepared by using the semiautomatic synthesis device.
出处 《同位素》 CAS 北大核心 2005年第4期233-236,249,共5页 Journal of Isotopes
关键词 化学合成模块 半自动化 氟标药物 chemistry synthesis module semiautomatic fluorine-18-labeled radiopharmaceuticals
  • 相关文献

参考文献8

  • 1Lim JL, Dorman ET, Cabral CL. Automated Production of [^18F]FECH and [^18F]FCH: Prepatat-ion and Use of [^18F]fluoroalkane Sulfonates as Flroroalkylation Agents[J]. J Label Compd Radiopharm, 2003, 46:S46.
  • 2Grierson JR, Shields AF. An Improved Radios-ynthesis of [^18F]FLT[J]. J Labelled Compd Ra-diopharm, 1999, 42:S525-S526.
  • 3吴战宏,王世真,周前,邱飞婵,霍力,滕宝,程欣.18~F标记氟乙基胆碱的合成与动物显像[J].中华核医学杂志,2005,25(3):138-140. 被引量:12
  • 4滕宝 王世真 傅喆.采用三种不同前体的3’-脱氧-3’-[^18F]氟胸腺嘧啶核苷半自动化合成[A]..第七次全国核医学学术会议论文摘要汇编[C].北京:中华核医学会,2005.119.
  • 5Machulla HJ, Blocher A, Kuntzsch M, et al. Simplified Labeling Approach for Synthesizing 3'-deoxy-3'-[^18F]fluorothymidine([^18F]FLT)[J]. Radianal Nucl Chem, 2000, 243(3):843-846.
  • 6Martin SJ, Eisenbarth JA, Wagner-Utermann U, et al. A New Precursor for the Radiosynthesis of [^18F]FLT[J]. Nucl Med Biol, 2002, 29: 263-273.
  • 7Barthel H, Cleij MC, Collingridge DR, et al. 3'-Deoxy-3'-[^18F]fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo With Positron Emission Tomography[J]. Cancer Res, 2003, 63:3791-3798.
  • 8Seung Jun Oh, Christoph Mosdzianowski, Dae Yoon Chi, et al. Fully Automated Synthesis System of 3'-Deoxy-3'-[^18F]fluorothymidine[J]. Nuclear Medicine and Biology, 2004, 31:803-809.

二级参考文献7

  • 1Hara T, Kosaka N, Kondo T, et al. Imaging of brain tumor, lung cancer,esophagus cancer, colon cancer, and bladder cancer with ^11C-choline [Abstract]. J Nucl Med, 1997, 38 Suppl: 250P.
  • 2Hasa T. ^18F-fluorocholine: a new oncologic PET tracer. J Nucl Mad,2001, 42: 1815-1817.
  • 3Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with11C-methyl choline. J Nucl Med, 1997, 38: 842-847.
  • 4Hara T, Kosaka N, Kishi H. Development of ^18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Mad, 2002, 43: 187-199.
  • 5Hara T, Yuasa M. Automated synthesis of ^18F-fluorine labeled choline analogue: 2-fluoroethyl-dimethyl-2-oxyethylammonium [ Abstract ]. J Nucl Mad, 1997, 38 Suppl: 44P.
  • 6DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of ^18F labeled choline as an oncologic tracer for positron emission tomography:initial findings in prostate cancer. Cancer Res, 2001, 61: 110-117.
  • 7DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of ^18F labeled choline analogs as oncologic PET tracers. J Nucl Med, 2001, 42:1805-1814.

共引文献11

同被引文献29

  • 1辛军,李宏利,郭启勇,赵周社.采用离子液体作为相转移催化剂一步法合成^(18)F-FLT的方法研究[J].中国临床医学影像杂志,2007,18(5):348-350. 被引量:1
  • 2Lee S J, Oh S J, Chi D Y, et al. Eur J Nucl Med Mol Imaging, 2007, 34:1406-1409.
  • 3Suehiro M, Vallabhajosula S, Goldsmith S J, et al. Appl Radia Isotopes, 2007, 65:1350-1358.
  • 4Buck A K, Schirrmeister H, Hetzel M, et al. Cancer Research, 2002, 62(12): 3331-3334.
  • 5Grierson J R, Shields A F, Eary J F. J Labelled Compd Radiopharm, 1997, 40:60-62.
  • 6Martin S J, Eisenbarth J A, Wagner-Utermann U, et al. Nucl Med Biol, 2002, 29:263-273.
  • 7Yun M, Oh S J, Ha H J, et al. Nucl Med Biol, 2003, 30:151-157.
  • 8Oh S J, Mosdzianowski C, Chi D Y, et al. Nucl Med Biol, 2004, 31:803-809.
  • 9Lee J H,Zhou H B,Dence C S. Development of[F-18]Fluorine-Substituted Tanaproget as a Pogesterone Receptor Imaging Agent for Positron Emission Tomography[J].{H}Bioconjugate Chemistry,2010.1096-1104.
  • 10Zhang P,Terefenko E,Kern J. 5-(3-Cyclopentyl-2-Thioxo-2,3-Dihydro-1H-Benzimidazol-5-yl)-1-Methyl-1H-Pyrrole-2-Carbonitrile:a Novel,Highly Potent,Selective,and Orally Active Non-Steroidal Progesterone Receptor Agonist[J].{H}Bioorganic and Medicinal Chemistry Letters,2007.6556-6564.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部